[PDF] Top 20 Sistema de logística inversa para el desarrollo sostenible de un astillero

... to temsirolimus by patients with MCL are higher than those reported by patients with renal cell carcinoma, breast cancer, lung cancer, and glioblastoma (about ...by lymphoma would be more sensitive ... See full document

... with relapsed or refractory MCL were randomized to receive temsirolimus 175 mg once weekly for 3 weeks followed by once-weekly doses of either 75 mg (175/75-mg regimen) or 25 mg (175/25-mg regi- ... See full document

... for relapsed MCL, such as thalidomide, lenalidomide, and fludarabine, among ...with temsirolimus at the 75 mg dose had a significantly longer PFS ...the temsirolimus arms than in the investigator’s ... See full document

... hematopoietic cell transplantation (HCT), 8–12 whereas older or un fi t patients are treated with less- intensive ...8–11 Relapsed MCL is a major therapeutic ...high treatment-related morbidity and ... See full document

... lenalidomide-based treatment, 17 patients responded (8 complete responses, 9 partial responses), for a 29% overall response rate (95% confidence interval, 18 – 43%) and a median duration of response of 20 weeks ... See full document

... the treatment of relapsed PTCLs in Japan in March ...include refractory patients; and 3) the incidence of secondary EBV-positive DLBCL (10%, 5 out of 48 patients) is relatively ... See full document

... the treatment of R/R PTCL, only the specific infections seen in ≥ 10% of patients (upper respiratory tract infection and sinusitis) were reported ...romidepsin treatment and thus may have been due to the ... See full document

... had relapsed after hema- topoietic stem cell transplantation (HSCT), including 4 who had relapsed after ASCT and 1 after allogeneic HSCT ...who relapsed after allo-HSCT accepted donor-derived ... See full document

... the treatment of classical Hodgkin lymphoma that has relapsed either after autologous stem cell transplantation (ASCT) or after two lines of combination chemotherapy in patients ineligible for ... See full document

... blockade treatment in solid tumors and hematological tumors (including malignant lymphoma) have been con- ducted ...non-small cell lung cancer, renal cell carcin- oma and squamous cell ... See full document

... in relapsed or refractory Hodgkin’s lymphoma (HL), and it has also shown its advantages in other CD30-positive ...the treatment of relapsed or refractory ... See full document

... producing cell cycle arrest or apoptosis of various transformed cells in vitro 30 ...provoke cell death in malignant cells in the course of multiple mechanisms, counting up regulation of death receptors and ... See full document

... [12] Kröger, N., Hoffknecht, M., Dreger, P., Krüger, W., Zeller, W., Krüll, A., et al. (1998) Long-term disease-free survi- val of patients with advanced mantle-cell lymphoma fol- lowing high-dose ... See full document

... ① Relapsed and re- fractory patients were mainly with ...stem cell transplantation was the ultimate choice of means in these ...Stem cell transplantation combin- ed with DC-CIK immunotherapy ... See full document

... non-Hodgkin’s lymphoma (NHL). Despite these advances, relapsed and refractory disease represents a major treatment ...for relapsed/refractory disease, including monoclonal ... See full document

... Abstract: Treatment of primary refractory and relapsed classical Hodgkin lymphoma remains challenging, with disappointing results overall and only a minority of patients enjoying a long- term ... See full document

... the treatment of relapsed and refractory indolent non-Hodgkin lymphoma ...for treatment of these ...lymphocytic lymphoma, multiple myeloma and mantle cell ... See full document

... B-cell lymphoma (PMBCL) is an unusually aggressive lymphoma, presumably originating from transformed thymic B ...B-cell lymphoma (DLBCL) with speci fi c clinical, immunohis- tochemical, ... See full document

... with relapsed/refractory peripheral T-cell lymphoma ...appropriate treatment modality has not been ...the treatment of T-cell ...the treatment of patients diagnosed ... See full document

... in cell survival and proliferation has made it an attractive target in cancer ...provide treatment alternatives across a range of malignancy ...Follicular lymphoma is one of the most common indolent ... See full document